Doris Chan

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III

Doris Chan, Gursharan Dogra, Ashley Irish et al. · Journal of Lipid Research · 2009 · 80 citations · Full text

Medicine, Biochemistry, Nephrology +17

Very Low Density Lipoprotein Metabolism and Plasma Adiponectin as Predictors of High-Density Lipoprotein Apolipoprotein A-I Kinetics in Obese and Nonobese Men

Dick C. Chan, P. Hugh R. Barrett, Esther Ooi et al. · The Journal of Clinical Endocrinology & Metabolism · 2008 · 65 citations · Full text

Life Sciences, Biochemistry, Endocrinology +16

Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease

Esther Ooi, Doris Chan, Gerald F. Watts et al. · Journal of Lipid Research · 2011 · 63 citations · Full text

Medicine, Biochemistry, Nephrology +5